Syngene International Limited hosted a plant visit to its Unit-3 for investors on September 9, 2025. The visit included an introduction to the facility, a tour of the Drug Substance unit and utility areas, and a Q&A session with the management.
The agenda for the visit was as follows:
Syngene acquired a multimodal biologics facility from Stelis Biopharma in December 2023, which includes integrated drug substance and commercial DP capability. This acquisition adds immediate capacity, enhances capabilities with a commercial-scale, high-speed fill-finish unit, and provides operational synergy by being located near Biocon Park.
The facility has a drug substance capacity of 20 KL, with potential for future expansion up to a further 20 KL. The acquisition was completed at a cost of ₹617 Crores (USD 75 Million), fully funded through internal accruals and cash. An additional $10 million is allocated for modification capex.
The facility was partially capitalized in Q1 FY26 and is focused on driving integrated projects across human and animal health. The strategic focus includes building a pipeline across human and animal health, integrated clinical manufacturing projects, and innovation for cost efficiency.
The Unit-3 site master plan includes a plot area of 22,000 m² (5.4 Acres). It consists of Block 1 (Expansion Area available), Block 2 - DS Block (2 Floors, one DS wing operational with 8 KL commissioned), Block 3 (Clinical DS (200L), 2 DP vial lines, QC, Admin), Utility Block 1 (Steam, Generator), and Utility Block 2 (WFI - Water for Injection).
During the site visit, participants were required to adhere to certain protocols, including minimum gowning, head cap, and shoe cover. Decorum is to be maintained while visiting labs, and Q&A should be limited to technical teams regarding infrastructure and plant details. A separate Q&A session will be held with Peter and Deepak to cover strategic and financial aspects.
The integration journey from acquisition to operation took 7 months. Key milestones include equipment qualification and area qualification in July 2024, with the first test batch initiated on July 15, 2024. Consistent facility performance has been achieved with multiple batches successfully executed with no facility-related issues.
The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
